At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 190 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
In Brief
A Phase 2 clinical trial evaluating Tirzepatide and Placebo for Nonalcoholic Steatohepatitis. Completed, enrolled 190 participants across 112 sites in 10 countries.
Detailed Summary
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Steatohepatitis
CountriesBelgium, France, Israel, Italy, Japan, Mexico, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartNov 2019
Primary CompletionDec 2023
Study CompletionJan 2024
TodayJul 2026
First PostedNov 18, 2019
Enrollment StartNov 19, 2019
Primary CompletionDec 11, 2023
Study CompletionJan 10, 2024
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 6.6 years ago
Interventions
Tirzepatidedrug
Administered SC
Placebodrug
Administered SC